Analysts Commentary
Guggenheim starts 'diamond in the rough' MyoKardia at Buy. Guggenheim analyst Etzer Darout started MyoKardia (MYOK) with a Buy rating, identifying the company and Zealand Pharma (ZEAL) as "diamonds in the rough" that are focused on therapies for cardiovascular and metabolic disorders and targeting therapeutic segments where patients are more homogenous and/or targets are validated. He currently value MYOK's mavacamten lead program in obstructive hypertrophic cardiomyopathy, or oHCM, at $63 per share with a 75% probability of success, Darout noted in his initiation. He set a $84 price target on MyoKardia shares.
Read more at:
thefly.com/land...ingPageNews.php?id=2965641...
Average analysts price target $80
Average analysts recommendation Buy
Short interest 11.2%
Company Profile
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.
Guggenheim starts 'diamond in the rough' MyoKardia at Buy. Guggenheim analyst Etzer Darout started MyoKardia (MYOK) with a Buy rating, identifying the company and Zealand Pharma (ZEAL) as "diamonds in the rough" that are focused on therapies for cardiovascular and metabolic disorders and targeting therapeutic segments where patients are more homogenous and/or targets are validated. He currently value MYOK's mavacamten lead program in obstructive hypertrophic cardiomyopathy, or oHCM, at $63 per share with a 75% probability of success, Darout noted in his initiation. He set a $84 price target on MyoKardia shares.
Read more at:
thefly.com/land...ingPageNews.php?id=2965641...
Average analysts price target $80
Average analysts recommendation Buy
Short interest 11.2%
Company Profile
MyoKardia, Inc. operates as a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The firm focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in San Francisco, CA.